Investigational Site Number :0320002

CABA, Buenos Aires C1425FVH

0 studies enrolling now · 11 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Asthma, Chronic Obstructive Pulmonary Disease, Cutaneous Lupus Erythematosus, Neurodermatitis, Non-small Cell Lung Cancer, Pleural Mesothelioma, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Studies at this site

• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma — Completed
• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Running, not enrolling
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) — Completed
• Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) — Completed
• Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) — Completed
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) — Stopped early
• Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME) — Completed
• Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia — Stopped early
• Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus — Completed
• Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation — Completed